Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
Neuro Oncol
; 25(2): 386-397, 2023 02 14.
Article
in En
| MEDLINE
| ID: mdl-35652336
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Central Nervous System Neoplasms
/
Rhabdoid Tumor
/
Antineoplastic Agents
Limits:
Child
/
Humans
Language:
En
Journal:
Neuro Oncol
Journal subject:
NEOPLASIAS
/
NEUROLOGIA
Year:
2023
Type:
Article
Affiliation country:
United States